Strong COVID-19 Response ACCURATE DIAGNOSTIC LABS has demonstrated a rapid and significant response to the COVID-19 pandemic by launching FDA EUA-approved saliva tests and partnering with government and healthcare entities to offer mass testing, indicating their capacity for scalable diagnostics and testing solutions.

Collaborative Innovation The company's collaborations with Rutgers University, RUCDR Infinite Biologics, and local health authorities highlight opportunities to develop and deploy innovative testing platforms, enabling expansion into new diagnostic markets and personalized testing services.

Expanding Market Presence With recent partnerships in Middlesex County and ongoing efforts to scale saliva-based testing, there is potential to grow geographically and diversify into broader health screening and infectious disease diagnostics beyond COVID-19.

Capable Tech Stack Utilizing advanced technologies such as Nginx, Google APIs, and WordPress, the company shows technical agility, which supports the development of user-friendly online platforms and data management solutions vital for expanding diagnostic service offerings.

Mid-Sized Growth Potential Operating with a revenue range of 10 to 25 million and a staff of 51 to 200, ACCURATE DIAGNOSTIC LABS is positioned as a mid-sized firm with growth opportunities in high-demand testing segments, making it attractive for partnerships with larger laboratory networks or health technology providers.